Curated Information
Javascript is not enabled on this browser. This site will not work properly without Javascript.
PhosphoSitePlus Homepage Cell Signaling Technology
PhosphoSitePlus
HomeAbout PhosphoSiteUsing PhosphoSiteCuration ProcessContact
NIH-logos NIGMS Logo NIAAA Logo NCI Logo NIH Logo
Curated Information Page
PubMed Id: 12900420 
This page summarizes selected information from the article referenced above and curated into PhosphoSitePlus®, a comprehensive online resource for the study of protein post-translational modifications (NAR, 2012,40:D261-70). To learn more about the scope of PhosphoSitePlus®, click here.
Salas TR, et al. (2003) Alleviating the suppression of glycogen synthase kinase-3beta by Akt leads to the phosphorylation of cAMP-response element-binding protein and its transactivation in intact cell nuclei. J Biol Chem 278, 41338-46 12900420
Only sites from this record are displayed on this page. Click on the protein name to open the protein page, and on the RSD number to open the site page. For the complete dataset, click the download button, on the right.
Download Sites

S129-p - CREB (human)
Orthologous residues
CREB (human): S129‑p, CREB iso2 (human): S115‑p, CREB (mouse): S129‑p, CREB (rat): S129‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  PC3 (prostate cell), prostate
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF increase
Associated Diseases
Diseases: Alterations: Comments:
prostate cancer increased high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer

S133-p - CREB (human)
Orthologous residues
CREB (human): S133‑p, CREB iso2 (human): S119‑p, CREB (mouse): S133‑p, CREB (rat): S133‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  PC3 (prostate cell), prostate
 Cellular systems studied:  cell lines, tissue
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
TNF no change compared to control
GSK3B (human) increase GSK3B S9 deletion mutant
Associated Diseases
Diseases: Alterations: Comments:
prostate cancer increased high in the low grade (well differentiated) and decreased in high grade (poorly differentiated) prostate cancer

S9-p - GSK3B (human)
Orthologous residues
GSK3B (human): S9‑p, GSK3B iso2 (human): S9‑p, GSK3B (mouse): S9‑p, GSK3B (rat): S9‑p, GSK3B (rabbit): S3‑p
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE Akt1 (human) inhibition of upstream enzyme
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LY294002 decrease
TNF decrease
TNF LY294002 augment treatment-induced decrease
EGF no change compared to control
EGF LY294002 decrease
IGF-1 no change compared to control
IGF-1 LY294002 decrease
insulin no change compared to control
insulin LY294002 no effect upon treatment-induced decrease
Downstream Regulation
 Effect of modification (function):  enzymatic activity, inhibited, intracellular localization, phosphorylation
 Effect of modification (process):  cell growth, altered
 Comments:  deletion of this site increases phosphoryaltion of CREB S133

Y216-p - GSK3B (human)
Orthologous residues
GSK3B (human): Y216‑p, GSK3B iso2 (human): Y216‑p, GSK3B (mouse): Y216‑p, GSK3B (rat): Y216‑p, GSK3B (rabbit):
Characterization
 Methods used to characterize site in vivo mutation of modification site, phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Treatments, proteins and their effect on site modification: 
Treatments Referenced Treatments Manipulated Protein Referenced Protein Effect Notes
LY294002 no change compared to control
TNF no change compared to control
TNF LY294002 no change compared to control
EGF no change compared to control
EGF LY294002 no change compared to control
IGF-1 no change compared to control
IGF-1 LY294002 no change compared to control
Downstream Regulation
 Effect of modification (function):  enzymatic activity, induced, intracellular localization
 Effect of modification (process):  transcription, induced

S63-p - Jun (human)
Orthologous residues
Jun (human): S63‑p, Jun (mouse): S63‑p, Jun (rat): S63‑p
Characterization
 Methods used to characterize site in vivo phospho-antibody, western blotting
 Relevant cell lines - cell types - tissues:  PC3 (prostate cell)
 Cellular systems studied:  cell lines
 Species studied:  human
Upstream Regulation
 Potential in vivo enzymes for site: 
Type Enzyme Evidence Notes
KINASE JNK1 (human) inhibition of upstream enzyme


Home  |  Curator Login With enhanced literature mining using Linguamatics I2E I2E Logo Produced by 3rd Millennium  |  Design by Digizyme
©2003-2013 Cell Signaling Technology, Inc.